These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 8499464)

  • 1. In-vitro stability and cytostatic activity of liposomal formulations of 5-fluoro-2'-deoxyuridine and its diacylated derivatives.
    van Borssum Waalkes M; van Galen M; Morselt H; Sternberg B; Scherphof GL
    Biochim Biophys Acta; 1993 May; 1148(1):161-72. PubMed ID: 8499464
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo distribution and antitumour activity of liposomal 3',5'-O-dipalmitoyl-5-fluoro-2'-deoxyuridine.
    Van Borssum Waalkes M; Fichtner I; Dontje B; Lemm M; Becker M; Arndt D; Scherphof GL
    J Microencapsul; 1992; 9(3):335-46. PubMed ID: 1403484
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The antitumour effect of lipophilic derivatives of 5-fluoro-2'-deoxyuridine incorporated into liposomes.
    Supersaxo A; Rubas W; Hartmann HR; Schott H; Hengartner H; Schwendener RA
    J Microencapsul; 1988; 5(1):1-11. PubMed ID: 2974073
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toxicity of liposomal 3'-5'-O-dipalmitoyl-5-fluoro-2'-deoxyuridine in mice.
    van Borssum Waalkes M; Goris H; Dontje BH; Schwendener RA; Scherphof G; Nijhof W
    Anticancer Drug Des; 1998 Jun; 13(4):291-305. PubMed ID: 9627669
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conversion of liposomal 5-fluoro-2'-deoxyuridine and its dipalmitoyl derivative to bile acid conjugates of alpha-fluoro-beta-alanine and their excretion into rat bile.
    van Borssum Waalkes M; Kuipers F; Havinga R; Scherphof GL
    Biochim Biophys Acta; 1993 Mar; 1176(1-2):43-50. PubMed ID: 8452878
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective transfer of a lipophilic prodrug of 5-fluorodeoxyuridine from immunoliposomes to colon cancer cells.
    Koning GA; Morselt HW; Velinova MJ; Donga J; Gorter A; Allen TM; Zalipsky S; Kamps JA; Scherphof GL
    Biochim Biophys Acta; 1999 Aug; 1420(1-2):153-67. PubMed ID: 10446299
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiproliferative effect of immunoliposomes containing 5-fluorodeoxyuridine-dipalmitate on colon cancer cells.
    Koning GA; Gorter A; Scherphof GL; Kamps JA
    Br J Cancer; 1999 Aug; 80(11):1718-25. PubMed ID: 10468287
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liposome-incorporated 3',5'-O-dipalmitoyl-5-fluoro-2'-deoxyuridine as a slow-release anti-tumor drug depot in rat liver macrophages.
    Van Borssum Waalkes M; Scherphof GL
    Sel Cancer Ther; 1990; 6(1):15-22. PubMed ID: 2140463
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of organ-specific immunoliposomes for delivery of 3',5'-O-dipalmitoyl-5-fluoro-2'-deoxyuridine in a mouse lung-metastasis model.
    Mori A; Kennel SJ; van Borssum Waalkes M; Scherphof GL; Huang L
    Cancer Chemother Pharmacol; 1995; 35(6):447-56. PubMed ID: 7882453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficient intracellular delivery of 5-fluorodeoxyuridine into colon cancer cells by targeted immunoliposomes.
    Koning GA; Kamps JA; Scherphof GL
    Cancer Detect Prev; 2002; 26(4):299-307. PubMed ID: 12430634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 5'-O-Palmitoyl- and 3',5'-O-dipalmitoyl-5-fluoro-2'-deoxyuridine--novel lipophilic analogues of 5'-fluoro-2'-deoxyuridine: synthesis, incorporation into liposomes and preliminary biological results.
    Schwendener RA; Supersaxo A; Rubas W; Weder HG; Hartmann HR; Schott H; Ziegler A; Hengartner H
    Biochem Biophys Res Commun; 1985 Jan; 126(2):660-6. PubMed ID: 3156589
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Liposomes as carriers of lipophilic cytosine arabinoside and fluorodeoxyuridine derivatives. Their cytostatic effect and possibilities of tumor cell specific therapy].
    Schwendener RA; Schott H; Hartmann HR; Supersaxo A; Rubas W; Hengartner H
    Onkologie; 1987 Aug; 10(4):232-9. PubMed ID: 2959889
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced brain targeting by synthesis of 3',5'-dioctanoyl-5-fluoro-2'-deoxyuridine and incorporation into solid lipid nanoparticles.
    Wang JX; Sun X; Zhang ZR
    Eur J Pharm Biopharm; 2002 Nov; 54(3):285-90. PubMed ID: 12445558
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic efficacy of a lipid-based prodrug of mitomycin C in pegylated liposomes: studies with human gastro-entero-pancreatic ectopic tumor models.
    Gabizon A; Amitay Y; Tzemach D; Gorin J; Shmeeda H; Zalipsky S
    J Control Release; 2012 Jun; 160(2):245-53. PubMed ID: 22134116
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotargeting of liposomes containing lipophilic antitumor prodrugs.
    Mori A; Kennel SJ; Huang L
    Pharm Res; 1993 Apr; 10(4):507-14. PubMed ID: 8483832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Controlled release of 5-fluoro-2'-deoxyuridine by the combination of prodrug and polymer matrix.
    Endoh H; Kawaguchi T; Seki T; Hasegawa T; Juni K
    Chem Pharm Bull (Tokyo); 1991 Feb; 39(2):458-64. PubMed ID: 1829027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Formulation optimization of an ephrin A2 targeted immunoliposome encapsulating reversibly modified taxane prodrugs.
    Huang ZR; Tipparaju SK; Kirpotin DB; Pien C; Kornaga T; Noble CO; Koshkaryev A; Tran J; Kamoun WS; Drummond DC
    J Control Release; 2019 Sep; 310():47-57. PubMed ID: 31400383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of stabilizing components on the integrity of antitumor liposomes loaded with lipophilic prodrug in the bilayer.
    Tretiakova D; Onishchenko N; Boldyrev I; Mikhalyov I; Tuzikov A; Bovin N; Evtushenko E; Vodovozova E
    Colloids Surf B Biointerfaces; 2018 Jun; 166():45-53. PubMed ID: 29533843
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Controlled release of 3',5'-diester prodrugs of 5-fluoro-2'-deoxyuridine from poly-L-lactic acid microspheres.
    Seki T; Kawaguchi T; Endoh H; Ishikawa K; Juni K; Nakano M
    J Pharm Sci; 1990 Nov; 79(11):985-7. PubMed ID: 2149864
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intracellular and serum stability of liposomal 2',3'-dideoxycytidine. Effect of lipid composition.
    Makabi-Panzu B; Gourde P; Désormeaux A; Bergeron MG
    Cell Mol Biol (Noisy-le-grand); 1998 Mar; 44(2):277-84. PubMed ID: 9593578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.